|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parish SL, Swaine JG, Son E and Luken K:
Determinants of cervical cancer screening among women with
intellectual disabilities: Evidence from medical records. Public
Health Rep. 128:519–526. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Diaz-Padilla I, Monk BJ, Mackay HJ and
Oaknin A: Treatment of metastatic cervical cancer: Future
directions involving targeted agents. Crit Rev Oncol Hematol.
85:303–314. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takekuma M, Kuji S, Tanaka A, Takahashi N,
Abe M and Hirashima Y: Platinum sensitivity and
non-cross-resistance of cisplatin analogue with cisplatin in
recurrent cervical cancer. J Gynecol Oncol. 26:185–192. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu M, Zhou X, Du Y, Huang Z, Zhu J, Xu J,
Cheng G, Shu Y, Liu P, Zhu W, et al: miR-20a induces cisplatin
resistance of a human gastric cancer cell line via targeting CYLD.
Mol Med Rep. 14:1742–1750. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mehta FF, Baik S and Chung SH: Recurrence
of cervical cancer and its resistance to progestin therapy in a
mouse model. Oncotarget. 8:2372–2380. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bi L, Ma F, Tian R, Zhou Y, Lan W, Song Q
and Cheng X: AJUBA increases the cisplatin resistance through hippo
pathway in cervical cancer. Gene. 644:148–154. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kumar D, Whiteside TL and Kasid U:
Identification of a novel tumor necrosis factor-alpha-inducible
gene, SCC-S2, containing the consensus sequence of a death effector
domain of fas-associated death domain-like
interleukin-1beta-converting enzyme-inhibitory protein. J Biol
Chem. 275:2973–2978. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kumar D, Gokhale P, Broustas C,
Chakravarty D, Ahmad I and Kasid U: Expression of SCC-S2, an
antiapoptotic molecule, correlates with enhanced proliferation and
tumorigenicity of MDA-MB 435 cells. Oncogene. 23:612–616. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Patel S, Wang FH, Whiteside TL and Kasid
U: Identification of seven differentially displayed transcripts in
human primary and matched metastatic head and neck squamous cell
carcinoma cell lines: Implications in metastasis and/or radiation
response. Oral Oncol. 33:197–203. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goldsmith JR and Chen YH: Regulation of
inflammation and tumorigenesis by the TIPE family of phospholipid
transfer proteins. Cell Mol Immunol. 14:10262017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang LJ, Liu X, Gafken PR, Kioussi C and
Leid M: A chicken ovalbumin upstream promoter transcription factor
I (COUP-TFI) complex represses expression of the gene encoding
tumor necrosis factor alpha-induced protein 8 (TNFAIP8). J Biol
Chem. 284:6156–6168. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao M, Xu Q, Lou C, Qin Y, Ning X, Liu T,
Zhao X, Jia S and Huang Y: Overexpression of TNFAIP8 is associated
with tumor aggressiveness and poor prognosis in patients with
invasive ductal breast carcinoma. Hum Pathol. 62:40–49. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun Z, Liu X, Song JH, Cheng Y, Liu Y, Jia
Y, Meltzer SJ and Wang Z: TNFAIP8 overexpression: A potential
predictor of lymphatic metastatic recurrence in pN0 esophageal
squamous cell carcinoma after Ivor Lewis esophagectomy. Tumour
Biol. 37:10923–10934. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Y, Jing C, Chen Y, Wang J, Zhou M, Liu
X, Sun D, Mu L, Li L and Guo X: Expression of tumor necrosis factor
α-induced protein 8 is upregulated in human gastric cancer and
regulates cell proliferation, invasion and migration. Mol Med Rep.
12:2636–2642. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang M, Zhao Q, Wang X, Liu T, Yao G, Lou
C and Zhang Y: TNFAIP8 overexpression is associated with lymph node
metastasis and poor prognosis in intestinal-type gastric
adenocarcinoma. Histopathology. 65:517–526. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu T, Gao H, Yang M, Zhao T, Liu Y and
Lou G: Correlation of TNFAIP8 overexpression with the
proliferation, metastasis, and disease-free survival in endometrial
cancer. Tumour Biol. 35:5805–5814. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang C, Chakravarty D, Sakabe I, Mewani
RR, Boudreau HE, Kumar D, Ahmad I and Kasid UN: Role of SCC-S2 in
experimental metastasis and modulation of VEGFR-2, MMP-1, and MMP-9
expression. Mol Ther. 13:947–955. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gus-Brautbar Y, Johnson D, Zhang L, Sun H,
Wang P, Zhang S, Zhang L and Chen YH: The anti-inflammatory TIPE2
is an inhibitor of the oncogenic Ras. Mol Cell. 45:610–618. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun H, Gong S, Carmody RJ, Hilliard A, Li
L, Sun J, Kong L, Xu L, Hilliard B, Hu S, et al: TIPE2, a negative
regulator of innate and adaptive immunity that maintains immune
homeostasis. Cell. 133:415–426. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lou Y and Liu S: The TIPE (TNFAIP8) family
in inflammation, immunity, and cancer. Mol Immunol. 49:4–7. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fayngerts SA, Wu J, Oxley CL, Liu X,
Vourekas A, Cathopoulis T, Wang Z, Cui J, Liu S, Sun H, et al:
TIPE3 is the transfer protein of lipid second messengers that
promote cancer. Cancer Cell. 26:465–478. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
You Z, Ouyang H, Lopatin D, Polver PJ and
Wang CY: Nuclear factor-kappa B-inducible death effector
domain-containing protein suppresses tumor necrosis factor-mediated
apoptosis by inhibiting caspase-8 activity. J Biol Chem.
276:26398–26404. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang TM, Barbone D, Fennell DA and
Broaddus VC: Bcl-2 family proteins contribute to apoptotic
resistance in lung cancer multicellular spheroids. Am J Respir Cell
Mol Biol. 41:14–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Low SY, Tan BS, Choo HL, Tiong KH, Khoo AS
and Leong CO: Suppression of BCL-2 synergizes cisplatin sensitivity
in nasopharyngeal carcinoma cells. Cancer Lett. 314:166–175. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cuadrado A and Nebreda AR: Mechanisms and
functions of p38 MAPK signalling. Biochem J. 429:403–417. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gupta J, del Barco Barrantes I, Igea A,
Sakellariou S, Pateras IS, Gorgoulis VG and Nebreda AR: Dual
function of p38α MAPK in colon cancer: Suppression of
colitis-associated tumor initiation but requirement for cancer cell
survival. Cancer Cell. 25:484–500. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ferrari G, Terushkin V, Wolff MJ, Zhang X,
Valacca C, Poggio P, Pintucci G and Mignatti P: TGF-β1 induces
endothelial cell apoptosis by shifting VEGF activation of
p38MAPK from the prosurvival p38β to proapoptotic p38α.
Mol Cancer Res. 10:605–614. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xiao S, Zhou Y, Yi W, Luo G, Jiang B, Tian
Q, Li Y and Xue M: Fra-1 is downregulated in cervical cancer
tissues and promotes cervical cancer cell apoptosis by p53
signaling pathway in vitro. Int J Oncol. 46:1677–1684. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wobus M, Kuns R, Wolf C, Horn LC, Köhler
U, Sheyn I, Werness BA and Sherman LS: CD44 mediates constitutive
type I receptor signaling in cervical carcinoma cells. Gynecol
Oncol. 83:227–234. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liao S, Xiao S, Zhu G, Zheng D, He J, Pei
Z, Li G and Zhou Y: CD38 is highly expressed and affects the
PI3K/Akt signaling pathway in cervical cancer. Oncol Rep.
32:2703–2709. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu JH, Liang XA, Wu YM, Li FS and Dai YM:
Identification of DNA methylation of SOX9 in cervical cancer using
methylated-CpG island recovery assay. Oncol Rep. 29:125–132. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dobo C, Stavale JN, Lima Fde O, Ribeiro
DA, Arias V, Gomes TS and Oshima CT: HSP27 is commonly expressed in
cervical intraepithelial lesions of Brazilian women. Asian Pac J
Cancer Prev. 14:5007–5010. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pei Z, Zhu G, Huo X, Gao L, Liao S, He J,
Long Y, Yi H, Xiao S, Yi W, et al: CD24 promotes the proliferation
and inhibits the apoptosis of cervical cancer cells in
vitro. Oncol Rep. 35:1593–1601. 2016. View Article : Google Scholar : PubMed/NCBI
|
